Antibiotic-Associated Diarrhea Clinical Trial
Official title:
A Double-blind, Randomized, Placebo-controlled, Single-center Study of the Efficacy and Safety of BIO-K+ CL-1285® in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection
Verified date | March 2012 |
Source | Bio-K Plus International Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to evaluate the efficacy and safety of Bio-K+ CL-1285 in the prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridum difficile-Associated Diarrhea (CDAD) in hospitalized patients exposed to nosocomial infection.
Status | Completed |
Enrollment | 255 |
Est. completion date | April 2009 |
Est. primary completion date | March 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 50 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Antibiotic therapy for a minimum of 3 days and a maximum of 14 days - Expected to remain hospitalized for a minimum of 5 days - Patients who have received less than 36 hours of antibiotic therapy - Negative pregnancy test at screening - Obtained his/her informed consent after verbal and written information - Patients having a telephone available (mobile, work, home) - Patients having a fridge at home Exclusion Criteria: - Pregnant or breastfeeding women - Patients presenting with active diarrhea (3 or more liquid stools per 24 hour period). - Patients with a history of daily consumption of probiotics, fermented milk and/or yogurt; - Patients known to have shown a previous reaction, including anaphylaxis, to any substance in composition of the study product (i.e. Non-medicinal ingredients: Cellulose, hypromellose, magnesium stearate (vegetal source), ascorbic acid, Colloidal silicon dioxide) - Patients presenting with an active, non-controlled intestinal disease such as Crohn's Disease or ulcerative colitis; - A previous documented C. Difficile infection < 3 months prior to study initiation ; - Ostomized patients, parenteral nutrition users - Patients with an immunosuppressive therapy or any health condition causing immunosuppression (including haematological malignancies, acquired immune deficiency syndrome (AIDS)) - Ongoing or recent use of antibiotic therapy in the 30 days prior to the study product first administration. - Patients with planned administration of antibiotics other than broad spectrum Penicillin, Cephalosporin or Clindamycin for the treatment of an infection; - Patients with concomitant participation in another clinical trial; - Patients who are not likely to comply with study requirements |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Bio-K Plus International Inc. | Sprim Advanced Life Sciences |
Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To Assess if Probiotic Prophylaxis (BIO-K+CL1285®) is Effective for the Prevention of AAD in Hospitalized Patients. | Incidence of AAD data were collected using questionnaire and diaries given to participants upon discharge. Diagnosis of AAD was made when a patient produced three or more liquid stools in a 24h period after antibiotic treatment with no other obvious reason for diarrhea. | Up to 40 days | No |
Secondary | Severity of AAD in Hospitalized Patients Ingesting BIO-K+CL1285® or Placebo. | Duration of diarrhea was determined by number of continuous days of diarrhea. Average number of liquid stools per day was determined by the sum of the number of liquid stools per day in the AAD episode divided by the duration of diarrhea in days. | Up to 40 days | No |
Secondary | Frequency of Stool Samples Positive for Clostridium Difficile (C. Difficile) Toxin A and/or B. | If diarrhea occured while hospitalized, patients provided a stool sample for C. difficile analysis of Toxin A and/or B. All episodes were recorded by a nurse of clinician on a case report form using the seven-item Bristol Stool Form Scale (Riegler et al., 2001). A diarrhea episode was described as a bowel movement consisting of watery stool with or without solids. | Up to 40 days | No |
Secondary | Safety Profile of BIO-K+CL1285® Versus Placebo in Hospitalized Patients. | Adverse events were reported by patients in the three study groups. | Up to 40 days | Yes |
Secondary | Frequencies of Other Gastrointestinal Symptoms. | Episodes of gastrointestinal disorders during hospitalization were recorded by patient interview and were confirmed by review of patient diaries. | Up to 40 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181516 -
Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics
|
Phase 2 | |
Recruiting |
NCT03895593 -
Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
|
||
Completed |
NCT00382304 -
A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea
|
Phase 2 | |
Completed |
NCT04212403 -
Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)
|
N/A | |
Terminated |
NCT02900196 -
Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders
|
N/A | |
Completed |
NCT01782755 -
Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial
|
Phase 2 | |
Completed |
NCT06109740 -
Probiotics For The Prevention of Antibiotics Associated Diarrhea in the Pediatric Intensive Care Unit
|
N/A | |
Suspended |
NCT00591357 -
Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy
|
Phase 4 | |
Completed |
NCT00700557 -
Probiotics at the Treatment of Antibiotic Associated Diarrhea
|
Phase 4 | |
Active, not recruiting |
NCT03256708 -
Prevention of Antibiotic-Associated Diarrhoea With Prolardii
|
N/A | |
Completed |
NCT04321460 -
Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.
|
Phase 3 | |
Completed |
NCT05607056 -
Efficacy and Safety of Sinquanon for Prevention of Antibiotic-associated Diarrhea in Adults
|
N/A | |
Recruiting |
NCT05845073 -
The Efficacy of a Probiotic for Antibiotic Associated Gastrointestinal Symptoms
|
N/A | |
Completed |
NCT01143623 -
Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults
|
Phase 2/Phase 3 | |
Completed |
NCT02127814 -
Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile
|
N/A | |
Completed |
NCT00641199 -
Probiotics for Prevention of Antibiotic-associated Diarrhea
|
N/A | |
Completed |
NCT02462590 -
Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial
|
Phase 4 | |
Terminated |
NCT01143272 -
Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea
|
Phase 3 | |
Completed |
NCT03755765 -
Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics
|
Early Phase 1 | |
Completed |
NCT05990972 -
Clinical Study of Fecal Microbiota Transplantation in the Treatment of Antibiotic-associated Diarrhea
|
N/A |